Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


For Sale: Knight Therapeutics Seeks Buyers For Impavido Priority Review Voucher

This article was originally published in The Pink Sheet Daily

Executive Summary

But the small Canadian specialty company says it will be patient in finding the maximum value for the asset, awarded in connection with FDA approval of its leishmaniasis treatment.


Related Content

Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less
Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain
PCSK9 Meets PRV: Regeneron’s $70 Mil. Bid To Catch Up To Amgen
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Priority Review Vouchers For Pediatric Rare Disease: Will Popularity Force A Quick Halt?
BioMarin Tests FDASIA’s Pediatric Voucher Waters With Vimizim Approval
Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts